Unknown back pain is caused by diffuse large B-cell lymphoma
A 70-year-old Taiwanese businessman suffers from frequent back pains. After seeing orthopedics and rehabilitation, he was unable to find relief. He was quite distressed. After several visits to Mackay Hospital for further imaging examinations of the spine, a tumor was found in the bone , after taking out the specimen, it was found to be lymphoma; it was further confirmed that it belongs to the relatively difficult diffuse large B-cell lymphoma (DLBCL) among the common non-Hodgkin’s lymphoma in China, and the cancer cells have spread to the body Everywhere, including bones, lungs, etc., was diagnosed as the third stage.
The patient complained of suffering from back pain for a long time, and hoped to relieve the pain quickly. The doctor suggested that the dual-target combination drug (P-RCHP) should be used as the initial treatment. Under the burden of receiving treatment. “After the patient started the treatment, his back pain was relieved immediately, and he didn’t even need to take painkillers. He has completed the course of treatment and is in good spirits. He is waiting for the next visit to arrange an imaging examination to confirm the condition.”
New treatment option for diffuse large B-cell lymphoma
Jiang Yihao, senior attending physician of the Department of Hematology and Oncology at Mackay Memorial Hospital in Taipei, pointed out that there are various types of lymphoma, and non-Hodgkin’s lymphoma is a more common type in clinical practice. According to Mackay’s experience, there are about 100 patients every year. It is roughly estimated that there are about 3,000 people in Taiwan.
“The incidence of non-Hodgkin’s lymphoma in Taiwan is much higher than that of Hodgkin’s, with a ratio of about nine to one.” He pointed out that DLBCL is a type of non-Hodgkin’s lymphoma, which is usually highly malignant and grows high speed. The first-line standard treatment for DLBCL is mainly R-CHOP. “In the past, when advanced DLBCL was treated with R-CHOP, about 50% of the patients could not be cured. Once relapsed, the prognosis is poor.”
Fortunately, at the end of last year, the Ministry of Health and Welfare approved the dual-target combination (P-RCHP) of a new generation of antibody-drug complexes and anti-CD20 monoclonal antibody chemotherapy as the first-line treatment for DLBCL. According to the 28-month follow-up data of the American Society of Hematology in 2021 in Asian populations, compared with R-CHOP, the 3-year progression-free survival period of the control group using P-RCHP exceeded 70%.
The initial symptoms are mild, and the vigilance is high, the chance of cure is high
Dr. Jiang Yihao said that from experience, P-RCHP is indeed effective in the first-line initial treatment. He used the aforementioned case to illustrate that the Taiwanese businessman originally needed to use high doses of painkillers to relieve back pain. After the administration of P-RCHP, the back pain was relieved and the quality of life was improved. “The benefit of using P-RCHP for this patient is that the dual-target combination drug replaces the chemotherapy drug (Oncovin) that affects the nerves. , just meet the requirements for relieving neuralgia, although there are still side effects of low white blood cells, but there are many clinical drugs that can treat it, and the safety is high.”
He reminded that the initial symptoms of lymphoma cancer are not obvious, and it is easy to confuse it with a mild cold and delay treatment. It is recommended to pay attention to whether there are any changes in life, such as finding that the cold has not healed for a long time, fever, inexplicable lumps on the body, night sweats, weight loss, etc. Fatigue, etc., need to be more vigilant, seek further medical examination, and deal with it as soon as possible to avoid deterioration.
2023-07-20 03:11:25
#Chronic #pain #unbearable #examination #caused #diffuse #large #Bcell #lymphoma #Life #CTWANT
